Vasc Spec Int.
2017 Sep;33(3):89-92. 10.5758/vsi.2017.33.3.89.
Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended?
- Affiliations
-
- 1Division of Vascular Surgery, Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece. georgegalyfos@hotmail.com
- 2Department of Microbiology, University of Athens Medical School, Areteion Hospital, Athens, Greece.
- KMID: 2396187
- DOI: http://doi.org/10.5758/vsi.2017.33.3.89
Abstract
- Cilostazol belongs to the new generation antiplatelet agents that have been introduced and studied regarding a potential role in cardiovascular disease prevention or treatment. Although data on peripheral artery disease are sufficient, and the drug has been recommended as first line treatment for intermittent claudication, it has not been approved nor recommended as far as cerebrovascular events are concerned. However, a great volume of randomized as well as pooled data has been published during the last years. Therefore, this review aims to describe the basic mechanisms of cilostazol's action as well as to present all recent clinical data in order to conclude on whether official guidelines should be extended.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Antiplatelet Therapy for Secondary Stroke Prevention: 2012 Focused Update of Korean Clinical Practice Guidelines for Stroke
- Secondary Prevention as Integral Part of Stroke Rehabilitation
- Pharmacological Secondary Prevention of Ischemic Stroke
- Antiplatelet Therapy for Secondary Stroke Prevention in Patients with Ischemic Stroke or Transient Ischemic Attack
- Focused Update of 2009 Korean Clinical Practice Guidelines for the Antiplatelet Therapy in Secondary Prevention of Stroke
